Acadia Pharmaceuticals (ACAD) Retained Earnings (2010 - 2026)

Acadia Pharmaceuticals' Retained Earnings history runs 17 years deep, the most recent figure standing at -$1.8 billion for Q1 2026.

• In Q1 2026, Retained Earnings fell 414230.21% year-over-year to -$1.8 billion; the TTM figure through Mar 2026 stood at -$1.8 billion (down 414230.21% YoY), while the FY2025 annual figure was $1.4 million, up 394.86% from the prior year.
• Retained Earnings for Q1 2026 stood at -$1.8 billion, down from $1.4 million in the prior quarter.
• The five-year high for Retained Earnings was $1.4 million in Q4 2025, with the low at -$2.4 billion in Q4 2023.
• The 5-year median for Retained Earnings is -$339000.0 (2024), against an average of -$941.1 million.
• The sharpest annual moves came in 2025 and 2026: Retained Earnings jumped 394.86% in 2025, then tumbled 414230.21% in 2026.
• Acadia Pharmaceuticals' Retained Earnings stood at -$2.4 billion in 2022, then decreased by 2.59% to -$2.4 billion in 2023, then jumped by 100.01% to $292000.0 in 2024, then jumped by 394.86% to $1.4 million in 2025, then plunged by 125342.15% to -$1.8 billion in 2026.
• Business Quant data shows ACAD's Retained Earnings at -$1.8 billion in Q1 2026, $1.4 million in Q4 2025, and $989000.0 in Q3 2025.